Agrylin Drug Use-Result Survey

Status Completed

Clinical Trial Summary

The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).

Clinical Trial Description

Anagrelide hydrochloride Drug Use-Result Survey ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03625895
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	November 25, 2014
Completion date	March 11, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01198717` - Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Completed	`NCT01467661` - Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia	Phase 3
Completed	`NCT01214915` - Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia	Phase 3
Active, not recruiting	`NCT02577926` - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Phase 2
Completed	`NCT01816256` - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms	N/A
Completed	`NCT01352585` - Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Completed	`NCT04243122` - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients	Phase 2